NASDAQ · SMMT
Healthcare · Biotechnology
$15.47
Down-$0.08 (-0.51%)
Updated Oct 26, 2026, 10:33 AM
SID Score
4.8/10
Composite research score
Smart Money
54/100
Neutral
Price performance · SMMT
1M range · 0 trading sessions · Daily adjusted prices
SMMT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning SMMT.
Company
Market Activity
Research & News
SMMT research
Filterable reporting and market headlines.
Filters are reflected in the page URL for sharing and back-button support.
5 matching articles.
Yahoo · Oct 24, 2026
Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab.
Yahoo · Oct 23, 2026
MIAMI & SEOUL, South Korea, October 23, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summit’s immuno-oncology development programs with ivonescimab.
Yahoo · Oct 22, 2026
MIAMI, October 22, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), taking place October 23-27, 2026, in Madrid, Spain.
Yahoo · Oct 21, 2026
Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.
Yahoo · Oct 21, 2026
Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemoth
The latest Smart Investors Daily articles mentioning SMMT.
